Няма налични фармакокинетични данни при пациенти с тежко чернодробно увреждане.
No dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, PREZISTA should be used with caution in these patients.